Patents by Inventor Tatsushi TODA

Tatsushi TODA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutic agent for diseases associated with abnormalities in dystroglycan sugar chain modification and method for assaying associated enzyme
    Patent number: 11040087
    Abstract: Provided is a therapeutic agent that effectively acts on a disease associated with abnormal glycosylation of dystroglycan. Also provided is a testing method for diseases associated with abnormal glycosylation of dystroglycan. Specifically, provided is a therapeutic agent for diseases associated with abnormal glycosylation of dystroglycan, containing CDP-ribitol as an active ingredient. Ribitol-phosphate is important in the glycan structure of dystroglycan. In order for ribitol-phosphate to be incorporated into a dystroglycan glycan, a material therefor (sugar donor) is required. In the present invention, it has been found for the first time that CDP-ribitol serves as the sugar donor. It has been confirmed that the glycan of ISPD-deficient cells can be restored by administering CDP-ribitol. Thus, the present invention, which allows CDP-ribitol to be utilized for supplementation therapy, has been completed.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: June 22, 2021
    Assignees: NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY, TOKYO METROPOLITAN GERIATRIC HOSPITAL AND INSTITUTE OF GERONTOLOGY, OSAKA PREFECTURAL HOSPITAL ORGANIZATION
    Inventors: Tatsushi Toda, Kazuhiro Kobayashi, Motoi Kanagawa, Tamao Endo, Hiroshi Manya, Yoshinao Wada, Michiko Tajiri
  • Therapeutic Agent For Diseases Associated With Abnormalities In Dystroglycan Sugar Chain Modification And Method For Assaying Associated Enzyme
    Publication number: 20200188491
    Abstract: Provided is a therapeutic agent that effectively acts on a disease associated with abnormal glycosylation of dystroglycan. Also provided is a testing method for diseases associated with abnormal glycosylation of dystroglycan. Specifically, provided is a therapeutic agent for diseases associated with abnormal glycosylation of dystroglycan, containing CDP-ribitol as an active ingredient. Ribitol-phosphate is important in the glycan structure of dystroglycan. In order for ribitol-phosphate to be incorporated into a dystroglycan glycan, a material therefor (sugar donor) is required. In the present invention, it has been found for the first time that CDP-ribitol serves as the sugar donor. It has been confirmed that the glycan of ISPD-deficient cells can be restored by administering CDP-ribitol. Thus, the present invention, which allows CDP-ribitol to be utilized for supplementation therapy, has been completed.
    Type: Application
    Filed: August 18, 2017
    Publication date: June 18, 2020
    Inventors: Tatsushi TODA, Kazuhiro KOBAYASHI, Motoi KANAGAWA, Tamao ENDO, Hiroshi MANYA, Yoshinao WADA, Michiko TAJIRI